APM - aptorumgroup.com Debt to Book Capitalization Ratio

Brandmark of Aptorum (APM)

The debt-to-equity ratio demonstrates the financial stability of Aptorum Group Limited, where the indicator is fixed at 0.15. The company is developing plant-based treatments for cancer and infections for future sales. However, its status as a bio-incubator creates risks due to fragmented projects and funding shortages. Meanwhile, the Hong Kong-based business successfully navigates geopolitical tensions by patenting its developments in the US.

Aptorum - APM Debts to Book Capitalization (period 07/04/2022 - 07/20/2026)
Flagship merchandise of Aptorum Group Ltd

Investors are evaluating the potential of Aptorum Group Limited (APM) through the lens of its capital resilience relative to debt obligations. This metric compares total borrowings against the book value of assets to determine the business's degree of financial leverage. Analyzing the ratio of financial debt to book capitalization allows for a real-time assessment of insolvency risk. For a biopharmaceutical ecosystem with a lengthy FDA approval cycle, low leverage is critically important, as it ensures the company's survival in the event of delays in the commercialization of new molecules.

Competitors of Aptorum Group Limited

Debt to Book Capitalization Ratio Haleon plc|kenvue.com - Debt to Net Assets Ratio|VRNA: Debt to Book Capitalization Ratio|MENS - Debt to Book Value|LGND: Debts to Book Capitalization|Debts to Book Capitalization Amneal Corp|PRGO - Debt to Book Value|Debt to Net Assets Ratio ALVO|Liquidia - Debt to Book Capitalization Ratio|Debts to Book Value Galapagos N.V. GLPG|Debt to Book Value ANI Pharma (ANIP)|Debt to Book Capital Afrezza MNKD|Debts to Book Capitalization Amphastar Pharmaceuticals (AMPH)|PCRX - Debt to Net Assets Ratio|Debts to Book Capitalization SPRY|TBPH (Theravance Biopharma Inc) - Debts to Book Value|AQST - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio scPharma|Debts to Book Capitalization TECX|Debts to Book Capitalization TNXP (tonixpharma.com)|China SXT Pharmaceuticals, Inc. (SXTC) - Debt to Book Capitalization Ratio|EPRX - Debts to Book Capitalization Ratio|Debt to Book Value BioHarvest BHST|EXOZ: Debt to Book Capital|Debt to Book Capitalization Ratio ORMP|ENTX (Entera Bio) - Debts to Book Value|HYFT - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ABVC BioPharma Inc. (ABVC)|Debt to Book Value CPIX|Debts to Book Capitalization QNTM (Quantum BioPharma Corp)|FibroGen, Inc. - Debt to Book Capitalization Ratio|TELO - Debt to Book Value|Debt to Book Value Rani Therapeutics Inc (RANI)|SNYR - Debt to Net Assets Ratio|Debts to Book Capitalization RLYB (rallybio.com)|LEXX (Lexaria Bioscience Corp.) - Debt to Net Assets|PULM - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio PTHL|Lyra Therapeutics - Debt to Book Capitalization Ratio|Debts to Book Value Impact BioMedical, Inc. IBO|Debt to Book Value TNFA (TNF Pharmaceuticals, Inc.)|cbdMD Inc. - Debts to Book Capitalization|Debt to Book Capitalization Ratio PainReform Ltd.|Altamira Therapeutics (CYTO) - Debts to Book Capitalization Ratio|Debt to Book Value Lipella Pharmaceuticals, Inc. LIPO|OPTN (OptiNose Inc) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Pieris|Debt to Book Capitalization Ratio Procaps Group Corp|PTPI (Petros Pharmaceuticals) - Debts to Book Capitalization|Debts to Net Assets QLI (qlsyy.net)|ACELYRIN - Debt to Book Capitalization Ratio|Debt to Book Value TFF Pharmaceuticals Inc. TFFP